NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
December 7, 2004 • Volume 1 / Number 47 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

The information and links on this page are no longer being updated and are provided for reference purposes only.

Funding Opportunities

Centers of Cancer Nanotechnology Excellence
RFA-CA-05-024
Letter of Intent Receipt Date: Feb. 25, 2005
Application Receipt Date: Mar. 25, 2005

NCI invites applications from investigators interested in participating in an initiative to establish up to five Centers for Cancer Nanotechnology Excellence (CCNEs). The intent of this RFA is to establish interdisciplinary research teams that collectively have the breadth of expertise not only to identify approaches, but also to validate and translate nanotechnology for a variety of cancer applications, up to and including pre-clinical testing. The overarching goals of the CCNE initiative are to design and test nanomaterials and nanodevices and to translate their use into clinical research, resulting ultimately in the introduction of novel diagnostic tools and techniques to modulate and overcome cancer processes. NCI's primary objective for this effort is to develop products and devices that constitute a new set of research tools for use by scientists in both the public and private sectors.

This funding opportunity will use the NIH U54 award mechanism.

For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2463.

Inquiries: Dr. Gregory J. Downing - downingg@mail.nih.gov

Multidisciplinary Career Development in Cancer Nanotechnology Research
RFA-CA-05-025
Application Receipt Date: Mar. 25, 2005

This RFA supports the career development of individuals from the basic, biomedical, clinical, and information sciences and engineering who are pursuing research that applies nanotechnology development and application for the prevention, detection, diagnosis, or treatment of cancer. The goal of this fellowship program in cancer nanotechnology research is to train highly skilled research scientists to develop and test nanomaterials and nanodevices and to apply these advances to address cancer-related issues. Awardees are expected to work as productive members of multidisciplinary research teams, assembled to address critical nanotechnology platform needs in cancer.

This funding opportunity will use the Kirschstein-NRSA F32 and F33 award mechanisms.

For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2462.

Inquiries: Dr. Gregory J. Downing - downingg@mail.nih.gov

Cancer Nanotechnology Platform Partnerships
RFA-CA-05-026
Letter of Intent Receipt Date: Feb. 25, 2005
Application Receipt Date: Mar. 25, 2005

NCI invites applications for research project grants (RPGs) to support development of nanotechnology platforms for basic, applied, and translational multidisciplinary research that uses nanotechnology (e.g., nanoscale devices or nanomaterials less than 1000 nm in size, although the assembly, synthesis, and/or fabrication of components at dimensions less than 300 nm should be demonstrated) in cancer research. Proposed projects will be eligible for consideration if they address one or more of the following thematic/programmatic areas of focus: molecular imaging and early detection, in vivo imaging, reporters of therapeutic efficacy, multifunctional therapeutics, prevention and control of cancer, and research enablers.

This funding opportunity will use the R01 award mechanism.

For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2461.

Inquiries: Dr. Gregory J. Downing - downingg@mail.nih.gov

Preventing Mitochondrial Oxidative Stress in Diabetes and Obesity
RFA-DK-05-001
Letter of Intent Receipt Date: Jan. 27, 2005
Application Receipt Date: Feb. 24, 2005

The objective of this RFA is to translate recent advances in understanding the mitochondrial ROS production associated with hyperglycemia to therapeutic interventions that would target mitochondrial ROS to prevent or ameliorate diabetic complications. Discovering and characterizing molecular targets, agents, and assays to prevent and measure the accumulation of mitochondrial ROS secondary to hyperglycemia would be appropriate research topics for this RFA. The proposed research should primarily focus at the cellular and subcellular level, but could expand to studies in tissues, organs, animal models, and small, pilot clinical studies. The choice of cell types and model systems should be appropriate for the pathophysiology of diabetic complications and nonalcoholic steatohepatitis.

This funding opportunity will use the R01 and R21 award mechanism(s).

For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2460.

Inquiries: Dr. Sharon Ross, MPH - rosssha@mail.nih.gov